About-cancer/treatment/clinical-trials/disease/melanoma/treatment
Hoʻomaʻamaʻa i nā hoʻokolohua lapaʻau no Melanoma
ʻO nā hoʻokolohua hoʻokolohua kahi noiʻi noiʻi e pili ana i ka poʻe. ʻO nā hoʻokolohua hoʻokolohua ma kēia papa inoa no ka mālama melanoma. Kākoʻo ʻia nā hoʻokolohua āpau ma ka papa inoa e NCI.
ʻO ka ʻike pili o NCI e pili ana i nā hoʻokolohua hoʻokolohua e wehewehe i nā ʻano a me nā pae o nā hoʻokolohua a pehea e lawe ai. Nānā nā hoʻāʻo hoʻokolohua i nā ala hou e pale ai, ʻike ai, a mālama ai paha i ka maʻi. E makemake paha ʻoe e noʻonoʻo e pili ana i ka lawe ʻana i ka hoʻokolokolo hoʻokolohua. E kamaʻilio me kāu kauka no ke kōkua i ka hoʻoholo ʻana inā kūpono kekahi iā ʻoe.
Nā hoʻāʻo 1-25 o 260 1 2 3 ... 11 Aʻe>
Hoʻonohonoho ʻia ka Therapy Therapy e alakaʻi ʻia e ka genetic Testing i ka mālama ʻana i nā mea maʻi me nā Tumors Refractory Solid Advanced, Lymphomas, a i ʻole Myeloma Multiple (The MATCH Screening Trial)
Ke nānā nei kēia pae II MATCH hoʻokolohua i ka maikaʻi o ke olakino e kuhikuhi ʻia e ka hoʻāʻo genetic i nā mea maʻi me nā tumors paʻa a i ʻole nā lymphomas i holomua ma hope o hoʻokahi laina o ka maʻamau maʻamau a i ʻole ʻaelike i kū ai ke ʻano lapaʻau. Nānā nā hoʻāʻo genetic i nā mea kūlohelohe (genes) o nā hunaola tumula o nā maʻi. ʻO nā mea maʻi me nā ʻano kūlohelohe (e like me ka hoʻololi ʻana, nā hoʻonui ʻana, a i ʻole nā translocations) ke ʻoi aku ka pōmaikaʻi mai ka hoʻomaʻamaʻa e kuhikuhi ana i nā kūlohelohe o kā lākou tumo. ʻO ka hoʻomaopopo ʻana i kēia mau ʻano kūlohelohe e kōkua mua paha i nā kauka e hoʻomaʻamaʻa maikaʻi aʻe no nā mea maʻi me nā tumors paʻa, lymphomas, a i ʻole myeloma he nui.
Kahi: 1189 mau wahi
Pembrolizumab i ka mālama ʻana i nā mea maʻi me ka pae III-IV Melanoma kiʻekiʻe kiʻekiʻe ma mua a ma hope o ke ʻoki ʻana
Ke aʻo nei kēia mahele II i ka hana ʻana o pembrolizumab ma mua a ma hope o ke kaha ʻana i ka mālama ʻana i nā mea maʻi me ka melanoma kūlana kiʻekiʻe III-IV. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku. ʻO ka hāʻawi ʻana i ka pembrolizumab ma mua a ma hope o ke kaha ʻana e hana ʻoi aku ka maikaʻi ma ka mālama ʻana i ka melanoma.
Kahi: 709 mau wahi
ʻO Dabrafenib a me Trametinib ukali ʻia e Ipilimumab a me Nivolumab a i ʻole Ipilimumab a me Nivolumab i ukali ʻia e Dabrafenib a me Trametinib i ka mālama ʻana i nā mea maʻi me ke kahua III-IV BRAFV600 Melanoma
Ke nānā nei kēia pae III i ka hoʻokolohua maikaʻi e pili ana i ka mālama mua ʻana me ipilimumab a me nivolumab ukali ʻia e dabrafenib a me trametinib hana a hoʻohālikelike ʻia i ka hana mua ʻana me dabrafenib a me trametinib ukali ʻia e ipilimumab a me nivolumab i ka mālama ʻana i nā mea maʻi me ka pae III-IV melanoma i loaʻa kahi hoʻololi i ʻike ʻia. BRAFV600 a ʻaʻole hiki ke hemo e ke ʻoki (unresectable). Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ipilimumab a me nivolumab, ke kōkua i ke kino o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūhaka tumo. Hiki iā Dabrafenib a me trametinib ke ālai i ka ulu ʻana o ka tumo ma ke kuhikuhi ʻana i ka ʻāpana BRAFV600.
Kahi: 712 mau wahi
ʻO Ipilimumab me a i ʻole Nivolumab i ka mālama ʻana i nā mea maʻi me Melanoma ʻo ia ka pae IV a i ʻole pae III a ʻaʻole hiki ke hemo ʻia e ka ʻoki kino.
Ke aʻo nei kēia pae II i ka maikaʻi o ka ipilimumab me a i ʻole me ka nivolumab hana i ka mālama ʻana i nā mea maʻi me ka melanoma ʻo ia ka pae IV a i ʻole ka pae III a ʻaʻole hiki ke hemo ʻia e ke ʻoki. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ipilimumab a me nivolumab, ke kōkua i ke kino o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūhaka tumora
Kahi: 600 mau wahi
Pembrolizumab i ka mālama ʻana i nā mea maʻi me Desmoplastic Melanoma i hiki ʻole a i ʻole hiki ke hemo ʻia e ke ʻoki kino.
Ke aʻo nei kēia pae hoʻokolohua II i ka hana maikaʻi ʻana o ka pembrolizumab i ka mālama ʻana i nā mea maʻi me ka desmoplastic melanoma (DM) i hiki a i ʻole hiki ke hemo ʻia e ke ʻoki (unresectable). Monoclonal antibodies, e like me pembrolizumab, hiki ke pale i nā protein i hiki ke hoʻoikaika i ka ʻōnaehana pale a kaohi i ka ulu ʻana o ka tumo.
Kahi: 202 mau wahi
ʻImi ʻIke o Entrectinib (RXDX-101) no ka mālama ʻana i nā mea maʻi me nā Tumors paʻa paʻa NTRK 1/2/3 (Trk A / B / C), ROS1, a i ʻole ALK Gene Rearrangements (Fusions)
ʻO kēia kahi lepili hāmama, multicenter, global Phase 2 hīnaʻi hoʻopaʻa haʻawina o entrectinib (RXDX-101) no ka mālama ʻana i nā mea maʻi me nā tumors paʻa e kūʻē ana i kahi NTRK1 / 2/3, ROS1, a i ʻole ALK gene fusion. E hāʻawi ʻia nā mea maʻi i nā ʻeke ʻokoʻa e like me ka tumo type a me ka gen fusion.
Kahi: 26 mau wahi
Ka palekana a me ka pono o Pembrolizumab Hoʻohālikelike ʻia i ka Placebo ma ke kūlana kiʻekiʻe kiʻekiʻe kiʻekiʻe II Melanoma (MK-3475-716 / KEYNOTE-716)
E loiloi kēia noiʻi ʻāpana ʻelua i ka palekana a me ka pono o ka pembrolizumab (MK-3475) i hoʻohālikelike ʻia i ka placebo i nā mea i komo me ka ʻokiʻoki ʻana i ka melanoma pae kiʻekiʻe II. E loaʻa i nā mea komo i ka ʻĀpana 1 kekahi pembrolizumab a i ʻole placebo i kahi hoʻolālā makapō makapō a 17 mau pōʻaiapili. ʻO nā mea komo i loaʻa kahi placebo a i ʻole e hoʻōki i ka lāʻau ma hope o ka loaʻa ʻana o 17 mau pōʻaiapuni o ka pembrolizumab i ka ʻĀpana 1, ʻaʻole ʻike i ka hoʻi hou ʻana o ka maʻi i loko o 6 mau mahina o ka hoʻopau ʻana i ka pembrolizumab ma ka ʻĀpana 1, a mai hōʻoki i ka mālama ʻana me pembrolizumab no ka hoʻi hou ʻana o ka maʻi a i ʻole ka hoʻomanawanui ʻole, hiki ke koho ʻia loaʻa iā 35 mau pōʻaiapuni hou o pembrolizumab i ka ʻĀpana 2 i kahi hoʻolālā hamama hāmama. ʻO ke kuhiakau mua o kēia aʻo ʻana ʻo ia ʻo pembrolizumab e hoʻonui i ke ola manuahi hoʻi ʻole (RFS) ke hoʻohālikelike ʻia i placebo.
Kahi: 25 mau wahi
ʻO Nivolumab me ka ʻole o Ipilimumab i ka mālama ʻana i nā mea ʻōpio me nā Tumors Solid a Refractory Solid paha a i ʻole Sarcomas
Ke aʻo nei kēia mahele I / II i nā hopena a me ka hopena maikaʻi loa o ka nivolumab ke hāʻawi ʻia me a i ʻole ʻole ipilimumab e ʻike i ke ʻano o kā lākou hana ʻana i ka mālama ʻana i nā mea ʻōpio me nā tumors paʻa a i ʻole nā sarcomas i hoʻi mai (recurrent) a i ʻole e pane i ka mālama refractory). Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab a me ka ipilimumab, ke kōkua i ka ʻōnaehana pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora. ʻAʻole i ʻike ʻia inā ʻoivolumab ka hana ʻoi aku ka maikaʻi a i ʻole me ka ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors paʻa hou a refactory a i ʻole sarcomas.
Kahi: 24 mau wahi
Ke aʻo ʻana o ka dose escalation and cohort expaced of NKTR-214 i ka hui pū ʻana me Nivolumab a me nā mea ʻē aʻe anti-cancer i nā mea maʻi me nā Tumors Solid Advanced (PIVOT-02).
Ma kēia haʻawina ʻehā ʻāpana, e lawelawe ʻia ʻo NKTR-214 me ka nivolumab ma ka ʻĀpana 1, me ka nivolumab me a i ʻole me nā chemotherapies ʻē aʻe i ka ʻĀpana 2, a me ka nivolumab a me ka ipilimumab i nā ʻĀpana 3 & 4. Ma ka ʻĀpana 1, ka Hoʻoholo ʻia ka Manaʻo Manaʻo 2 (RP2D) o NKTR-214 i ka hui pū ʻia ʻana me nivolumab. Ma ka ʻĀpana 2, NKTR-214 me ka nivolumab ma ka RP2D e loiloi ʻia ma ke ʻano he lalani mua a me / a i ʻole ma ke ʻano he laina ʻelua a ʻekolu paha i nā mea maʻi i koho ʻia me Melanoma, Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC ), Urothelial Carcinoma (UC), metastatic Breast Cancer (mBC) a me Colorectal Cancer (CRC). Hoʻohui ʻia, i ka ʻāpana 2, e hoʻoholo ʻia ka RP2D o NKTR-214 me nā nivolumab a me nā chemotherapies like ʻole a me nā regimens i nā kohoko koho o nā mea maʻi NSCLC. Ma ka Mahele 3, e loiloi i kekahi mau regimens like ʻole o ka huina pākolu o NKTR-214 plus nivolumab a me ipilimumab i nā mea maʻi i wae ʻia me RCC, NSCLC, Melanoma, a me UC. Ma ka ʻĀpana 4, e loiloi hou ʻia ka palekana a me ka pono o ka huina pākolu ma nā koho maʻi me RCC, NSCLC, Melanoma a me UC.
Kahi: 22 mau wahi
Ke aʻo 1 / 1b e loiloi ai i ka palekana a me ke ahonui o CPI-444 wale nō a me ka hui pū ʻana me Atezolizumab i nā Cancers Advanced.
ʻO kēia kahi ʻāpana 1 / 1b hāmama-lepili, multicenter, hoʻopaʻa haʻawina koho o CPI-444, kahi mole liʻiliʻi waha e kuhikuhi ana i ka adenosine-A2A receptor ma nā T-lymphocytes a me nā pūnaewele ʻē aʻe o ka ʻōnaehana paleʻea. E hoʻopaʻa ana kēia hoʻokolohua i ka palekana, ka hoʻomanawanui, a me ka hana anti-tumor o CPI-444 ma ke ʻano he agena hoʻokahi a me ka hui pū ʻana me atezolizumab, kahi mea kāohi PD-L1 e kūʻē i nā tumors paʻa like ʻole. CPI-444 ālai adenosine mai ka hoʻopili ʻana i ka mea loaʻa iā A2A. Hoʻopau ʻo Adenosine i ka hana anti-tumor o nā hunaola T a me nā hunaola ʻē aʻe.
Kahi: 22 mau wahi
Ke aʻo ʻana o Pembrolizumab (MK-3475) i nā mea komo i nā keiki me kahi Tumor Solid Advanced a i ʻole Lymphoma (MK-3475-051 / KEYNOTE-051)
ʻO kēia kahi noiʻi ʻelua ʻāpana o ka pembrolizumab (MK-3475) i nā haumāna pediatric i loaʻa kekahi o nā ʻano maʻi ʻaʻai: - melanoma holomua (6 mau mahina a i <18 mau makahiki), - holomua, hoʻi hou a refactory papahana papahana- ligand 1 (PD-L1) -positive malignant tum tum solid a i ʻole lymphoma ʻē aʻe (6 mau mahina a i <18 mau makahiki), - hoʻi hou a refactory paha Hodgkin lymphoma (rrcHL) (3 mau makahiki i <18 mau makahiki), a i ʻole - holomua relapsed a i ʻole refractory microsatelit-instability-high (MSI-H) paʻa tumors (6 mau mahina a i <18 mau makahiki). E ʻike ka ʻāpana 1 i ka mahele lāʻau i ʻae ʻia (MTD) / ka palena ʻoi loa o ka lāʻau i lawelawe ʻia (MAD), e hōʻoia i ka mahele lāʻau, a e ʻike i ka paukū Phase 2 i koi ʻia (RP2D) no ka lāʻau pembrolizumab Ma ka ʻāpana 2 e loiloi hou i ka palekana a me ka pono ma ka pediatric RP2D. ʻO ke kuhiakau mua o kēia noi ʻo ia ka lawelawe intravenous (IV) o ka pembrolizumab i nā keiki me kekahi melanoma holomua; kahi PD-L1 maikaʻi i holomua, hoʻi hou a i ʻole refactory paʻa tumo a i ʻole lymphoma ʻē aʻe; holomua, hoʻi a hoʻi ʻole i ka tumor paʻa paʻa MSI-H; a i ʻole rrcHL, e hopena i kahi pahuhopu pane pahuhopu (ORR) ʻoi aku ma mua o 10% no hoʻokahi o kēia ʻano maʻi ʻaʻai. Me ka Hoʻololi 8, ke kākau inoa ʻana o nā mea komo me nā tumors paʻa a me nā mea komo mai 6 mau mahina a <12 mau makahiki me ka melanoma i pani ʻia. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo mai ≥12 makahiki a ≤18 mau makahiki me ka melanoma. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo me nā tumors paʻa MSI-H. relapsed a refactory MSI-H paʻa paʻa puʻupuʻu; a i ʻole rrcHL, e hopena i kahi pahuhopu pane pahuhopu (ORR) ʻoi aku ma mua o 10% no hoʻokahi o kēia ʻano maʻi ʻaʻai. Me ka Hoʻololi 8, ke kākau inoa ʻana o nā mea komo me nā tumors paʻa a me nā mea komo mai 6 mau mahina a <12 mau makahiki me ka melanoma i pani ʻia. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo mai ≥12 makahiki a ≤18 mau makahiki me ka melanoma. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo me nā tumors paʻa MSI-H. relapsed a refactory MSI-H paʻa paʻa puʻupuʻu; a i ʻole rrcHL, e hopena i kahi pahuhopu pane pahuhopu (ORR) ʻoi aku ma mua o 10% no hoʻokahi o kēia ʻano maʻi ʻaʻai. Me ka Hoʻololi 8, ke kākau inoa ʻana o nā mea komo me nā tumors paʻa a me nā mea komo mai 6 mau mahina a <12 mau makahiki me ka melanoma i pani ʻia. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo mai ≥12 makahiki a ≤18 mau makahiki me ka melanoma. Ke hoʻomau nei ke kākau inoa ʻana i nā mea komo me nā tumors paʻa MSI-H.
Kahi: 19 mau wahi
Ka palekana a me ka pono o IMCgp100 Versus Investigator Choice ma Advanced Uveal Melanoma
E loiloi i ke ola holoʻokoʻa o HLA-A * 0201 mau maʻi makua maikaʻi me UM i holomua mua i loaʻa iā IMCgp100 i hoʻohālikelike ʻia i ka Choice Investigator's Choice o dacarbazine, ipilimumab, a i ʻole pembrolizumab.
Kahi: 18 mau wahi
ʻO Enapotamab Vedotin (HuMax-AXL-ADC) Ke aʻo palekana ma nā mea maʻi me nā tumors paʻa
ʻO ke kumu o ka hoʻokolokolo ʻana e hoʻoholo i ka palena lāʻau i ʻae ʻia a me ka hoʻokumu ʻana i ka ʻike palekana o HuMax-AXL-ADC i kahi lehulehu o nā mea maʻi me nā tumors paʻa ponoʻī.
Kahi: 18 mau wahi
Ke aʻo ʻana o XmAb®20717 i nā kumuhana me nā Tumors Solid Advanced i wae ʻia
ʻO kēia kahi pae 1, nā mahele lāʻau he nui, e piʻi nei i ka hoʻonui ʻana o ka lāʻau e wehewehe ai i ka MTD / RD a me ka regimen o XmAb20717, e wehewehe i ka palekana a me ka hoʻomanawanui ʻana, e loiloi iā PK a me ka immunogenicity, a me ka loiloi mua i ka hana anti-tumor o XmAb20717 i nā kumuhana me ke koho nā tumors paʻa holomua.
Kahi: 15 mau wahi
ʻO Talimogene Laherparepvec a me Pembrolizumab i ka mālama ʻana i nā mea maʻi me ke kahua III-IV Melanoma
Ke aʻo nei kēia mahele II i ka maikaʻi o ka talimogene laherparepvec a me ka pembrolizumab e hana nei i ka mālama ʻana i nā mea maʻi me ka melanoma pae III-IV. ʻO nā mea olaola biological, e like me talimogene laherparepvec, hoʻohana i nā mea i hana ʻia mai nā meaola e hiki ai ke hoʻoulu a kāohi paha i ka ʻōnaehana pale pale ma nā ʻano like ʻole a kāpae i nā hunaola ulu ulu. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka talimogene laherparepvec a me ka pembrolizumab i ka mālama ʻana i nā mea maʻi me ka melanoma e ka hoʻoliʻiliʻi ʻana i ka tumo.
Kahi: 16 mau wahi
ʻO Dabrafenib, Trametinib, a me Navitoclax i ka mālama ʻana i nā mea maʻi me ka BRAF Mutant Melanoma a i ʻole nā Tumors Paʻa i Metastatic a i ʻole hiki ke lawe ʻia e ka ʻoki kino.
Ke aʻo nei kēia mahele I / II i nā hopena a me ka hopena ʻoi loa o dabrafenib, trametinib, a me navitoclax a ʻike i ka maikaʻi o kā lākou hana ʻana i ka mālama ʻana i nā mea maʻi me ka BRAF mutant melanoma a i ʻole nā tumors paʻa i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino a i ʻole hiki ke hemo ʻia. ma ke ʻoki kino. Hiki i ka Dabrafenib, trametinib, a me ka navitoclax ke hoʻōki i ka ulu ʻana o nā hunaola puʻupuʻu ma ke kāpae ʻana i kekahi o nā enzyme e pono ai no ka ulu ʻana o ka cell.
Kahi: 24 mau wahi
Ke aʻo ʻana no Avelumab i ka hui pū ʻana me nā Immunotherapies Ka maʻi ʻaʻai ʻē aʻe i nā maʻi maʻi holomua (JAVELIN Medley)
ʻO kēia kahi Phase 1b / 2 hoʻopaʻa haʻawina optimization e loiloi i ka palekana, nā lāʻau lapaʻau, nā lāʻau lapaʻau, a me nā hana antitumor mua o avelumab (MSB0010718C) i hui pū ʻia me nā maʻi pale maʻi maʻi ʻē aʻe i nā mea maʻi me nā tumors solid kūloko a metastatic paha. ʻO ke kumu mua e nānā i ka palekana a me nā hōʻailona mua o ka pono o nā hui like ʻole avelumab me nā maʻi maʻi maʻi ʻē aʻe, e hoʻonui ana i nā regimen dosing e like me ka mea kūpono, i loko o kahi moʻo o nā hōʻike.
Kahi: 12 mau wahi
ʻO kahi noiʻi Immuno-therapy noiʻi e loiloi i ka palekana, ke ahonui a me ka hopena o Anti-LAG-3 Me a me ka ʻole o Anti-PD-1 i ka mālama ʻana i nā Tumors paʻa.
ʻO ke kumu o ke aʻo ʻana e nānā i ka palekana, ka hoʻomanawanui a me ka maikaʻi o ka lāʻau hoʻokolohua BMS-986016 i lawelawe hoʻokahi ʻia a me ka hui pū ʻana me nivolumab i nā mea maʻi me nā tumors paʻa i pālahalaha a / a i ʻole hiki ʻole ke hemo e ke ʻoki. Hoʻokomo ʻia kēia ʻano tumo ma kēia noi: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, pūpū maʻi puʻuwai pūpū, maʻi ʻaʻai o ka maʻi ʻaʻai, maʻi kanesa squamous cell o ke poʻo a me ka ʻāʻī, a me ka melanoma, ʻaʻole ma mua. mālama ʻia me ka maʻi pale. NSCLC a me melanoma i mālama ʻia ma mua me ka pale maʻi pale.
Kahi: 12 mau wahi
ʻO kahi palekana, Tolerability a me PK Study o DCC-2618 i nā mea maʻi me nā maʻi maʻi holomua
ʻO kēia kahi Phase 1, open-label, first-in-human (FIH) dose-escalation study i hoʻolālā ʻia e loiloi i ka palekana, hoʻomanawanui, pharmacokinetics (PK), pharmacodynamics (PD) a me ka hana antitumor mua o DCC-2618, lawelawe waha ʻia. (PO), i nā mea maʻi makua me nā maʻi kūpilikiʻi loa. Aia i loko o ka noiʻi nā ʻāpana 2, kahi pae hoʻonui ʻana a me kahi manawa hoʻonui.
Kahi: 12 mau wahi
Ke aʻo ʻana o NKTR-214 i hui pū ʻia me Nivolumab me Nivolumab wale nō i nā mea komo me ka hana ʻole ʻole Metastatic Melanoma ma mua.
ʻO ke kumu o ke aʻo ʻana e hoʻāʻo i ka pono (ka maikaʻi o ka hana ʻana o ka lāʻau), palekana, a me ka hoʻomanawanui ʻana i ka lāʻau noiʻi i kapa ʻia ʻo NKTR-214, ke hui pū ʻia me ka nivolumab me ka nivolumab i hāʻawi wale ʻia i nā mea komo me ka maʻi ʻaʻai melanoma i hana ʻole ʻia ma mua. hiki ʻole ke hoʻoneʻe ʻia a pāhola paha
Kahi: 10 mau wahi
Ke aʻo ʻana o Relatlimab Plus Nivolumab Versus Nivolumab wale nō i nā mea komo me ka Melanoma holomua.
ʻO ke kumu o kēia noi ʻana e hoʻoholo inā ʻoivolumab i hui pū ʻia me relatlimab ʻoi aku ka maikaʻi ma mua o ka nivolumab e ia iho i ka mālama ʻana i ka melanoma unresectable a i ʻole ka melanoma i pāhola ʻia.
Kahi: 13 mau wahi
Pembrolizumab a me Ipilimumab i ka mālama ʻana i nā mea maʻi me ka Melanoma holomua i mālama ʻia ma mua
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana ʻana o ka pembrolizumab a me ka ipilimumab i ka mālama ʻana i nā mea maʻi me ka melanoma i hana mua ʻia i hoʻolaha ʻia i nā ʻāpana ʻē aʻe o ke kino. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab a me ipilimumab, ke kōkua i ke kino pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora
Kahi: 10 mau wahi
Haʻawina Haumana o CMP-001 i ka Hoʻohui Me Pembrolizumab a i ʻole me he Monotherapy
E mālama ʻia kēia haʻawina i ʻelua mau ʻāpana: E mālama ʻia ka ʻāpana 1 me ka hoʻohana ʻana i kahi hoʻolālā Dose Escalation a me Expansion. ʻO ka ʻāpana 1 piʻi ʻana o ka hana e ʻike ʻia kahi mahele lāʻau palekana a hoʻomanawanui ʻia e loiloi hou ʻia i ka ʻāpana Hoʻonui Dose Hoʻonui. E mālama ʻia ka ʻāpana 2 o ke aʻo ʻana me ka ʻāpana Hoʻonui Hoʻonui Dose ʻĀpana a e loiloi i ka palekana a me ka pono o CMP-001 ke lawelawe ʻia ma ke ʻano he monotherapy.
Kahi: 12 mau wahi
ʻO ka hoʻāʻo 1b / 2 o Lenvatinib (E7080) Plus Pembrolizumab i nā kumuhana me nā tumors paʻa i wae ʻia.
This is an open-label Phase 1b / 2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase 1b (lenvatinib 20 mg / day orally + pembrolizumab 200 mg Q3W, IV).
Location: 10 locations
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
ʻO ka Prospective, study multicenter intervalent loiloi i ka cell therapy (ACT) ma o ka hoʻokomo ʻana o LN-144 (autologous TIL) ukali ʻia e interleukin 2 (IL-2) ma hope o kahi lymphodepletion nonmyeloablative (NMA LD).
Kahi: 13 mau wahi
1 2 3 ... 11 Aʻe>
